SCHEMBL5896348

SCHEMBL5896348

CCn1ccnc1Cn1ccnc1-c1cccc(F)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.37
KMT2A Q03164 5/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ADRA2B P18089 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
CYP2C19 P33261 1/20 0.36
ABCB11 O95342 1/20 0.36
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
MEN1 O00255 3/20 0.35
BRD4 O60885 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPK1 P28482 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5896841 0.84 BRD4 (0.32) KMT2ABRD4MAPT
SCHEMBL5896427 0.82 BRD4 (0.31) BRD4
SCHEMBL5896460 0.82 BRD4 (0.31) BRD4
SCHEMBL3061489 0.81 S1PR1 (0.34) KMT2AALDH1A1MEN1BRD4RAB9A
SCHEMBL3070588 0.81 TP53 (0.38) KMT2AALDH1A1KDM4EMEN1MAPT
SCHEMBL5896578 0.79 MEN1 (0.31) KMT2AALDH1A1KDM4EMEN1BRD4
SCHEMBL5896693 0.79 NPY5R (0.34) KMT2AALDH1A1KDM4EMEN1RAB9A
SCHEMBL5897411 0.79 HPGDS (0.33) ALDH1A1KDM4ECYP3A4CYP2C19BRD4
SCHEMBL13089471 0.79 GRM2 (0.35) KCNH2
SCHEMBL3061416 0.78 RPS6KA5 (0.43) KMT2AALDH1A1CYP2D6CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030144-B2 Substituted imidazole derivatives: GABAA receptor ligands NEUROGEN CORPORATION (US) 2006-04-18 US claimed
EP-1499608-A1 SUBSTITUTED IMIDAZOLE DERIVATIVES: GABA A RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2005-01-26 EP claimed
US-20040002608-A1 Substituted imidazole derivatives: GABAA receptor ligands NEUROGEN CORPORATION 2004-01-01 US claimed
WO-2003093263-A1 SUBSTITUTED IMIDAZOLE DERIVATIVES: GABAA RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2003-11-13 WO claimed
EP-1499608-A1 SUBSTITUTED IMIDAZOLE DERIVATIVES: GABA A RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2005-01-26 EP disclosed
WO-2003093263-A1 SUBSTITUTED IMIDAZOLE DERIVATIVES: GABAA RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002608-A1 Substituted imidazole derivatives: GABAA receptor ligands GABRA1, GABRA3, GABRA2 KCNH2 1017/4885KMT2A 2328/4885ALDH1A1 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.